Rankings / Mitochondria & Cellular Energy

BAM15

Mitochondria & Cellular Energy · Mitochondrial uncoupler / exercise mimetic

Tier D

High-risk evidence profile

wadamitochondrial-uncouplerresearch-chemicalbanned-sport
High-risk evidence profile
2.9 / 10
Tier D
Ev 2 Bn 5 Sf 3

Bottom line

Read Off Label grades BAM15 as D (2.9/10) based on preclinical evidence, unclear benefit magnitude, and a unknown-high-risk safety profile.

Its high-risk evidence profile reflects a Safety score of 3/10; reported benefits and harms can differ by indication, dose, route, duration, and population.

WADA coverage: 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine/BAM15.

Studied, labeled, or reported-use context: No approved human dose — Research chemical; WADA S4 prohibited; not individualized guidance.

What the evidence says

WADA coverage: 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine/BAM15. DNP already has its own high-risk row; BAM15 is added separately because it is a named WADA metabolic modulator.

Mechanism

BAM15 is a mitochondrial protonophore explored preclinically for obesity/metabolic disease; it sits in the same conceptual danger zone as uncoupling-for-fat-loss compounds.

Studied, labeled, or reported dose & route

No approved human dose

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about BAM15's effects?
Read Off Label rates the evidence for BAM15 as Preclinical and the benefit magnitude as unclear, producing an overall grade of D (2.9/10). WADA coverage: 5-N,6-N-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine/BAM15.
What safety findings are reported for BAM15?
BAM15 has a unknown-high risk profile in the database. Unknown-High (uncoupler class concerns: hyperthermia, narrow safety margin, off-target mitochondrial toxicity) Legal status: Research chemical; WADA S4 prohibited.
What does the low Safety score for BAM15 represent?
The Safety score is 3/10. It records the substantial harms described for one or more use contexts; the Benefit score, indication, dose, route, duration, population, and legal status remain separate parts of the evidence profile.
What doses or routes are reported for BAM15?
No approved human dose This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does BAM15 work?
BAM15 is a mitochondrial protonophore explored preclinically for obesity/metabolic disease; it sits in the same conceptual danger zone as uncoupling-for-fat-loss compounds.

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.